2019 American Transplant Congress
Successful Kidney Transplant Improves Glucose Tolerance – A Paradoxical Report From A Single Center
Kidney Transplantation Surgery, Sapporo City General Hospital, Sapporo, Japan
*Purpose: Kidney recipients tend to impair glucose tolerance because of several factors such as post-operative obesity, and chronic exposure of some diabetogenic immunosuppressants like calcineurin…2019 American Transplant Congress
Microfluidic Study Analyzing the Effect of Immediate-Release and Extended-Release Tacrolimus on Islet Function
*Purpose: The purpose of this analysis was to quantify the impact of 2 tacrolimus pharmacokinetic profiles on functional changes within human islet cells using a…2019 American Transplant Congress
Natural Course Of Tacrolimus Intra-patient Variability In Liver Transplant Recipients
University of Cincinnati, Cincinnati, OH
*Purpose: The evolution of tacrolimus (TAC) intra-patient variability (IPV) post liver transplant (LT) remains to be characterized. Identification of factors associated with high TAC-IPV may…2018 American Transplant Congress
Presence of Chronic Vascular Lesions on Allograft Biopsy is Associated with Greater Improvement in Renal Function after Conversion from Tacrolimus to Belatacept
Background: Conversion from tacrolimus to belatacept has been shown to be beneficial for an increasing number of kidney transplant (KT) patients. However, predicting factors for…2018 American Transplant Congress
Long Term Outcomes of a Steroid Free, Low Dose Tacrolimus with Everolimus Regimen in Kidney Transplant
Tacrolimus (Tac) is the most effective immunosuppressive agent to prevent acute allograft rejection. However, long-term transplant (Tx) outcomes are limited, at least in part, by…2018 American Transplant Congress
Superiority of Early Everolimus-Based Quadruple Immunosuppression versus Standard Triple Therapy after Lung Transplantation: 12 Months Results from Prospective 4EVERLUNG Study in Germany
The 4Everlung trial was designed to evaluate the benefit of early everolimus (EVR)-based quadruple low immunosuppressive (IS) regimen on kidney function (RF) after LTx.4EVERLUNG is…2018 American Transplant Congress
Effect and Reasons of Rescue Switch to Belatacept among 73 Calcineurin-Inhibitors Treated Kidney Allograft Recipients – A Three Years Retrospective Cohort, Single Center Study
IntroductionAfter kidney transplantation, long-term immunosuppression with calcineurin inhibitors (CNIs) or mTOR inhibitors (mTORi) leads to adverse effects, such as nephrotoxicity and proteinuria. Currently, available data…2018 American Transplant Congress
Clinical Outcomes of Conversion from Calcineurin Inhibitor to Belatacept-Based Immunosuppression in Highly Sensitized Kidney Transplant Recipients
Cedars Sinai Medical Center, Los Angeles.
Introduction:Efficacy of belatacept when converted from calcineurin inhibitors (CNI) in high immunologic risk patients has not been established. We examined the impact of HLA-sensitization on…2018 American Transplant Congress
Calcineurin Inhibitors, Macrolides, and the Risk of Adverse Drug Events in Kidney Transplant Recipients
1Univ of Alberta, Edmonton, Canada; 2Univ of Calgary, Calgary, Canada; 3Saint Louis Univ, St. Louis.
Background: After kidney transplantation, calcineurin inhibitors (CNIs, cyclosporine, tacrolimus) are key components of immunosuppression but have multiple potential drug interactions. Macrolide antibiotics are often used…2018 American Transplant Congress
Impact of Direct Acting Antivirals of Hepatitis C Virus Therapy on Tacrolimus Dosing Post-Liver Transplant
Michigan Medicine, Ann Arbor, MI.
Background: Direct acting antivirals (DAA) have transformed hepatitis C virus (HCV) management post-liver transplant (LT). As HCV clears, hepatic metabolism improves, resulting in decreased tacrolimus…
- « Previous Page
- 1
- …
- 6
- 7
- 8
- 9
- 10
- …
- 16
- Next Page »